Select Page

PMBCL

Articles

– Outcome –  

2013 Dunleavy et al.

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

2014 Martelli et al.

FDG PET predicts survival after Chemoimmunotherapy for PMBCL - Results of the International Extranodal Lymphoma Study Group IELSG-26 Study

2014 Romejko-Jarosinska et al.

Relapsed or refractory primary mediastinal B-cell lymphoma: Evaluation of outcome of a minority from 125 patients treated at a single institution

2014 Nagle et al.

The role of FDG-PET imaging as a prognostic marker of outcome in PMBCL

2015 Tavares et al.

Treatment Outcomes of Patients with Primary Mediastinal Diffuse Large B-Cell Lymphoma: A Single-Center Experience

2015 Pinnix et al.

Single-institution experience in the treatment of PMBCL tretaed with Immunochemotherapy in the Setting of response assessment by FDG PET

2016 Kocurek et al.

Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy

2017 Giulino-Roth et al.

Outcomes of adults and children with PMBCL treated with DA-EPOCH-R

2017 Ceriani et al.

Prognostic models for PMBCL derived from 18-FDG PET/CT quantitative parameters in the IELSG 26 study

2017 Barrington et al.

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

2018 Pinnix et al.

Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL

2018 Melani et al.

End-of-treatment and serial PET imaging in PMBCL following DA/EPOCH-R, a paradigm shift in clinical decision making

2018 Ceriani et al.

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

CATEGORIES